Trials / Completed
CompletedNCT00388180
An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation
A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 71 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The investigational drugs administered in this study activate proteins called PPARs. Data in the scientific literature on PPARs, as well as animal data and early clinical data generated by GSK with these drugs, suggest that activation of PPARs may cause the body to increase its use of fatty acids for energy, and lead to a reduction in body fat. There are also data to suggest a role for PPARs in regulating lipid (e.g., cholesterol) levels and inflammation. These and other activities of PPARs are being further explored in this clinical study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW501516 | |
| DRUG | GW590735 |
Timeline
- Start date
- 2004-12-01
- First posted
- 2006-10-16
- Last updated
- 2012-03-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00388180. Inclusion in this directory is not an endorsement.